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Aim: Cystatin C, neutrophil gelatinase-associated lipocalin (NGAL) and galectin-3 have 
emerged as biomarker candidates to predict cardiovascular outcomes and mortality in 
the general population as well as in patients with coronary artery or renal disease. 
However, their predictive role and clinical utility in patients with acute coronary 
syndromes (ACS) alone or in combination beyond currently used risk scores remains to 
be determined. 
Methods and Results: Cystatin C, NGAL, and galectin-3 were measured in 
plasmas of 1’832 patients at the time of presentation with ACS requiring percutaneous 
coronary intervention or coronary artery bypass grafting. The primary outcomes were 
major adverse cardiac and cerebrovascular events (MACCE) (defined as the composite 
of all-cause mortality, cerebrovascular events, any repeat revascularization or 
myocardial infarction) and all-cause mortality after 1 year and occurred in 192 (10.5%) 
and 78 (4.3%) of patients, respectively. All three biomarkers were increased in those 
with MACCE compared with those without (p<0.001). However, only galectin-3 (all-
cause mortality: HR=1.027 [95%CI(1.011-1.043);p=0.001], MACCE: HR=1.025 
[95%CI(1.012-1.037);p<0.001]) but not cystatin C nor NGAL emerged as independent 
predictors of both MACCE and death. The risks were particularly high in the highest 
quartile of galectin-3. The integration of galectin-3 into the GRACE score improved the 
prediction of MACCE and all-cause mortality significantly. The areas under the receiver 
operator characteristics curves increased from 0.6701 to 0.6932 for MACCE (p = 
0.0474) and from 0.804 to 0.8199 for all-cause mortality (p = 0.0197). Finally, we applied 
Net Reclassification Improvement (NRI) index using different cut-offs for MACCE which 
showed negative results (for the cut-offs of 5% and 15%, NRI 0.028, P = 0.586, for the 
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cut-offs of 10% and 20%, NRI 0.072, P = 0.1132 and for the cut-offs of 10% and 30% 
the NRI is 0.0843, P = 0.077). 
Conclusions: In ACS patients, galectin-3 has moderate prognostic accuracy, provides 
statistically significant incremental value in some, but not all models, and that the 
























Cardiovascular (CV) diseases remain the number one cause of deaths worldwide 
with atherosclerosis as its main underlying cause (1). The formation of plaques, 
particularly those with a soft and destabilizing lipid-rich core provides the substrate for 
acute coronary syndromes (ACS) and stroke, which due to superimposed thrombosis 
may lead to vascular obstruction, organ ischemia or death (2).  
Risk scores have been developed for a more tailored management of patients 
with ACS. Indeed, with the advent of effective, but costly novel drugs in secondary 
prevention, risk scores are even more important to address the remaining risk in those 
affected (3). The commonly used GRACE score, is based on age, heart rate, systolic 
blood pressure, renal function, congestive heart failure, ST-deviation, cardiac arrest and 
cardiac biomarkers (4).  
Biomarkers have significantly improved the diagnosis and risk assessment of 
ACS, in particular cardiac troponin I (cTnI) and T (cTnT), both components of the 
contractile apparatus of myocytes. (5, 6). Furthermore, B-type natriuretic peptide BNP 
and its N-terminal NTproBNP are of great clinical value (7). Finally, C-reactive protein 
(CRP) and white blood cell counts, both markers of inflammation, predict outcome (8-
10).  
Cystatin C, neutrophil gelatinase-associated lipocalin (NGAL) and galectin-3 
have emerged as biomarker candidates to predict cardiovascular outcomes and 
mortality in the general population as well as in patients with coronary artery or renal 
disease. However, their predictive role and clinical utility in patients with acute coronary 
syndromes (ACS) alone or in combination beyond currently used risk scores remains to 
be determined. 
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By the use of a multi-marker approach we here explored the prognostic value of 
cystatin C, NGAL and galectin-3 in a large prospective cohort of patients with ACS 
managed according to current guidelines and determined the incremental value of these 





Patient population: 1’832 patients from the SWISS Special Program University 
Medicine in ACS (SPUM-ACS) cohort were included in the study (SPUM ACS; 
NCT01000701) with documentation in a central database and biobank. 267 patients with 
informed consent were excluded either due to failure to analyse the blood in the 
dedicated biomarker kit or failure of biomarker measurement. Clinical endpoints were 
censored at last contact date for 32 patients due to no follow up (supplementary figure 
1). The cohort comprised of those patients presenting to one of four participating Swiss 
University Hospitals (Zurich, Bern, Lausanne, and Geneva) between December 2009 
and October 2012 with a diagnosis of ACS (STEMI, NSTE-ACS or unstable angina) 
requiring percutaneous coronary intervention (PCI) or coronary artery bypass grafting.  
 
Patient Selection: Included patients had symptoms compatible with angina pectoris 
(chest pain, dyspnea) of less than 5 days duration and fulfilled at least one of the 
following criteria: (a) ECG changes such as persistent ST-segment elevation or 
depression, T-inversion or dynamic ECG changes, new left bundle branch block (LBBB);  
(b) evidence of positive  (predominantly conventional) troponin by local laboratory 
reference values with a rise and/or fall in serial troponin levels; (c) known coronary artery 
disease, specified as status after myocardial infarction, previous PCI or newly 
documented ≥50% stenosis of an epicardial coronary artery during the initial 
catheterization. Exclusion Criteria were Patients refusal of informed consent to 
participate in the registry or lack capacity to consent including foreign languages, High 
probability of non-adherence to follow-up requirements including patients with sever 
disabilities and Tourists. 
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Events Adjudication: All-cause mortality included cardiac, vascular and non-
cardiovascular causes of death. Cerebrovascular events comprised stroke (any, 
ischemic, hemorrhagic, unclear etiology) or transient ischemic attack (TIA); Repeat 
revascularization included any repeat coronary revascularization (target and non-target 
vessel). Clinically indicated repeat revascularization included any clinically driven repeat 
coronary revascularization (target and non-target vessel). Myocardial infarction (MI) was 
defined based on the universal definition including peri-procedural Myocardial infarction 
in patients with unstable angina. The primary endpoint of our study and adjudicated 
major adverse cardiovascular and cerebrovascular events (MACCE), defined as the 
composite of all-cause mortality, cerebrovascular events, any repeat revascularization 
or myocardial infarction at 1-year. The secondary end points were adjudicated major 
adverse cardiovascular events (MACE) defined as the composite of cardiac death, 
clinically indicated revascularization or MI at 1 year. MACCE were adjudicated by an 
independent committee of experienced cardiologists (Matthias Pfisterer, MD; Lukas 
Kappenberger, MD and Tiziano Moccetti, MD).  
  
Biomarkers: Cystatin C, NGAL and galectin-3 were measured in serum sample 
obtained directly after insertion of the sheath, before performing the diagnostic 
angiography. Although the time between presentation of the patients to angiography 
may affect the relative values of individual biomarkers this is unlikely to play a major role 
as STEMI patients were taken to the catheterization laboratory within minutes of 
presentation and NSTEMI patients underwent angiography almost always within hours 
of presentation. Concentrations of Galectin-3 as well as neutrophil gelatinase associated 
lipocalin (NGAL) in plasma were measured by the use of chemiluminescent microparticle 
immunoassays (CMIA) on the Architect immunoanalyser (Abbott Laboratories, 
 8 
Wiesbaden, Germany) (11, 12). Cystatin C was measured in plasma by the use of a 
particle enhanced turbidimetric immunoassay from Gentian on the Architect Ci8000 
analyser (Abbott) by Analytica (Zurich, Switzerland) (13). All assays were performed in 
a central core  laboratory (AvE; Institute for Clinical Chemistry, University Hospital 
Zurich, Switzerland). 
 
Ethics: The study was approved by the local ethical committees (Kantonale 
Ethikkomission Zürich, Switzerland; project ID EK-1688). All patients gave written 
informed consent and all data was anonymized and controlled on site by a dedicated 
study nurse, all in compliance with the Declaration of Helsinki (14) and the current ICH 
Guidelines for Good Clinical Practice (15,16). Of note Abbott Laboratories (Wiesbaden, 
Germany) provided the biomarker assays free of charge but had no role in the statistical 
evaluation of data and the writing of the manuscript. 
 
Statistics: Continuous variables are expressed as mean ± standard deviation (SD) or 
medians with interquartile ranges, and were compared using one way ANOVA, Student’s 
t-test, Kruskal-Wallis or Mann-Whitney as appropriate. Categorical data are presented 
as frequency (percentages) and were compared using the Fisher exact or the chi-square 
test. We performed univariate regression to determine the predictors of the outcome. 
Significant predictors of the primary outcome in a univariate analysis were included in 
multivariate regression model. The choice was mainly determined by clinical and 
statistical relativity to the studied outcome as well as being meaningful in daily practice. 
The smoothHR package on R was used for Pointwise Nonparametric Estimation of 
hazard ratio curves for the continuous variable Galectin-
3.  (Cite:  https://doi.org/10.1155/2013/745742). All statistical analyses including logistic 
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regression were performed with SPSS 22 and differences were considered significant 
at α = 0.05.  
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RESULTS 
Univariate correlations and associations of the three biomarkers with MACCE and 
all-cause mortality 
The primary end points of MACCE and all-cause mortality occurred in 192 (10.5%) and 
78 (4.3%) of patients at 1 year, respectively. Clinical and procedural characteristics in 
patients with and without MACCE are summarized in Table 1.  
Upon univariate analysis, all three biomarkers were associated with both MACCE and 
mortality (Supplementary Appendix Table 1). In receiver operator characteristics 
(ROC) curve analysis (Figure 1), the prognostic performance of the unadjusted 
biomarkers did not differ significantly from each other, neither for all-cause mortality 
(AUCGalectin-3 = 0.751 vs. AUCCystatin C = 0.761 vs. AUCNGAL = 0.721) nor for MACCE 
(AUCGalectin-3 = 0.622 vs. AUCCystatin C = 0.632 vs. AUCNGAL = 0.592).   
 
Predictive Value of Galectin-3 for Adverse Cardiac Events and All-cause Mortality 
Upon regression analysis, the three markers correlated significantly with each other and 
by similar strength: r2 (cystatin C vs. NGAL) = 0.517, r2 (cystatin C vs. galectin-3) = 
0.491),  and r2 (galectin-3 vs NGAL) = 0.497 (acceptable collinearity VIF <5, tolerance 
>0.2). Also, serum creatinine levels correlated strongly with all three markers, the 
strongest being cystatin C with r2 = 0.583 (p<0.001).  
 
Galectin-3 but neither cystatin C nor NGAL are independent prognostic 
biomarkers towards MACCE and all-cause mortality 
Multivariate Cox regression model analysis was used to assess the predictors of 
MACCE and all-cause mortality. After adjusting for age, troponin, myocardial infarction, 
CABG, history of malignancy, heart failure with reduced ejection fraction (EF<50%), 
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insulin-dependent diabetes mellitus, resuscitation, galectin-3, NGAL, cystatin C and 
GFR, the only significant and independent predictors of both MACCE and all-cause 
mortality during one year of follow-up were age, insulin-treated diabetes mellitus, a 
history of malignancy, and galectin-3. In addition troponin T was an independent 
predictor of death (Table 2). The hazard ratios of galectin-3 with the one-year-risks of 
MACCE and all-cause mortality amounted to 1.025 [95%CI(1.012-1.037)]; p<0.001) and 
1.027 [95%CI(1.011-1.043)] p = 0.001), respectively. Neither Cystatin C nor NGAL were 
independent predictors of MACCE (HR=0.814 [95%CI(0.518-1.279] and HR  = 1.001 
[95%CI(0.998-1.005], respectively) or all-cause mortality (HR = 0.919 [95%CI(0.557-
1.519] and HR=1.003 [95%CI(0.999-1.008], respectively) (Table 2). 
 
Detailed prognostic properties of galectin-3  
The analysis of separate spline curves for hazard ratios showed the presence of 
a nonlinear, dose-response relationship between serum levels of galectin-3 and risk of 
both MACCE and all-cause mortality (figure 2). To further substantiate our findings, 
patients were subdivided into quartiles according to the plasma galectin-3 
concentrations (Q1:<11.5 ng/ml, Q2:11.5-14.3ng/ml, Q3:14.3-18.3ng/ml, Q4>18.3) and 
evaluated for the incidence of MACCE and death per quartile (Table 3). In Q4, there 
was a significantly (p<0.001) higher number of MACCE as well as deaths compared to 
the lower three quartiles (MACCE: Q4 16.8% vs Q3 10%vs Q2 8.7% vs Q1 6.5% and 
all-cause mortality: Q4 10.2% vs Q3 3.6% vs Q2 2.4% vs Q1 1.1%). The cumulative 
survival rate in galectin-3 in the Q4 group was significantly lower than in the Q1, Q2 and 
Q3 groups (p<0.001) as seen in the Kaplan Meier curve analysis (Figure 3). 
We assessed the incremental predictive value of galectin 3 in addition to the 
GRACE score.  For MACCE, Galectin 3 significantly improved the AUC of the ROC 
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curve from 0.6701 (95% asymptotic CI 0.614 – 0.726) to 0.6932 (0.636 – 0.750) (p = 
0.0474, (Figure 4a).  For all cause mortality, Galectin 3 significantly improved the AUC 
from 0.804 (95% CI 0.749 – 0.858) to 0.820 (0.766 – 0.874), p = 0.0197 (Figure 4b).                                    
Finally, we applied Net Reclassification Improvement (NRI) index using two risk 
cut-offs of 5% and 15% for MACCE, showed a NRI of 0.02822 (std error 0.05194), P = 
0.58688 (also for cut-offs of 10% and 20% the NRI is 0.0723, P = 0.1132 and cut-offs of 








The most important finding of our study is that [1] We demonstrated in a multi-marker 
strategy that out of three renal biomarkers evaluated in this large prospective cohort of 
patients with ACS, only galectin-3, but not cystatin C or NGAL provided independent, 
but only modest incremental prognostic information for MACCE and repeat 
revascularization in some, but not all models (taking into account the negative result 
obtained from NRI analysis). As such, galectin-3 on its own is not a promising biomarker 
for further personalized guidance of therapy in patients with ACS. However, in the 
context of a risk algorithm as artificial intelligence is now about to provide, it may 
contribute to a more personalized risk assessment. [2] Particularly high galectin-3 
plasma levels were associated with a higher incidence of the aggregated endpoint 
encompassing repeat angina or ACS, arrhythmia or cardiac arrest, congestive heart 
failure, stroke and cardiac or cerebrovascular death compared to low galectin-3 levels. 
[3] Finally, MACCE increased with increasing galectin-3 levels in a non-linear fashion. 
Thus, particularly patients in the upper quartile of galectin-3 levels exhibited a markedly 
increased MACCE rate and mortality and thus a reduced long-term survival.
 Several studies, mostly with low patient numbers, have studied the role of 
galectin-3 alone, rather than in comparison with other novel markers as investigated in 
this study. In a small and short-term case control study with 196 STEMI patients and 30 
healthy controls galectin-3 levels were higher in STEMI patients than healthy controls 
and those with high galectin-3 had a higher 30-day MACE and mortality rate (17). 
However, although ROC analysis suggested galectin-3 levels ≥7.67 ng/mL to be a 
predictor of 30-day MACE, the sensitivity and specificity were relatively low with 74.5% 
and 72.4%, respectively (18). Similarly, in another underpowered study of 433 patients 
with STEMI, NSTEMI, stable CAD and healthy controls high galectin-3 concentrations 
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were associated with an increased risk of all-cause mortality (19,20). In contrast, another 
small retrospective study involving only 112 patients with STEMI, previous infarction and 
controls could not confirm these findings (21). Similarly, Martin-Reyes et al. evaluating 
270 patients with prior ACS concluded that galectin-3 was not an independent predictor 
of MACE (22). While these small and in part retrospective single-centre studies yielded 
contradictory results, our large prospective multicentre registry with independent and 
blinded adjudication and a central core lab clearly establishes galectin-3 as an 
independent predictor of outcome in ACS patients. 
There are several possible explanations for the prognostic value of galectin-3. 
First, galectin-3 destabilizes atherosclerotic plaques as it propagates inflammation, 
attracts monocytes and macrophages and promotes the formation of foam cells, which 
secrete galectin-3 and further activate macrophages (32-25). Galectin-3 also 
dedifferentiates vascular smooth muscle cells, further contributing to plaque vulnerability 
and ACS (26, 27) In apolipoprotein-E deficient mice, inhibition of galectin-3 not only 
reduces plaque volume and M2 macrophage activation, but also plaques (28). This has 
been confirmed in Apo-E-Galectin-3 double-knockout mice in which not only 
inflammation and adventitial infiltrates were reduced, but also atheromatous plaques 
(29). Second, as patients with high galectin-3 exhibit more inflammation they also 
develop bigger infarcts and in turn lower LVEF. Indeed, three smaller studies found an 
inverse relation between LVEF and galectin-3 levels in ACS patient (19, 30-32). This 
may facilitate the development of heart failure during follow-up in those with high 
galectin-3 levels. Indeed, galectin-3 predicts heart failure hospitalisations and mortality 
(33). This may be related to the fact that galectin-3 promotes myocardial cardiac fibrosis, 
thus resulting in maladaptive cardiac remodelling. As galectin-3 is strongly associated 
with GFR it may be involved in both cardiac and renal dysfunction (34, 35) Overall, this 
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suggests that galectin-3 is not only a potent predictor of outcome, but also a potential 
therapeutic target. Blockade of galectin-3 in patients after ACS might not only reverse 
the atherosclerotic process, but also slow down the development and progression of 
heart failure.  
 Cystatin C is a protease inhibitor and its main function is to protect cells from 
hydrolysis by endogenous and exogenous proteases (36). As such, cystatin C is not 
only a marker of GFR, but also predicts outcomes in CAD or ACS. Indeed, in 605 ACS 
patients, Sun et al. found significantly higher plasma cystatin C levels in patients with 
MACE even after adjustment for confounding factors (37). Although we could confirm 
these findings, cystatin C did not remain an independent predictor of MACCE and all-
cause mortality after adjusting for confounders. Thus, our results obtained in a large 
prospective cohort dispute these previous studies (38 – 40) and dispute the usefulness 
of cystatin C in ACS patients. In line with our results, Jernberg et al. comparing cystatin 
C, creatinine and GFR found that cystatin C was superior in seperating survivors and 
non-survivors at 35 months. However, after adjustment for variables associated with 
outcome, cystatin C was also no longer an independent predictor of outcomes (41).  
 Neutrophil gelatinase-associated lipocalin or NGAL is a 25kD acute phase 
glycoprotein and a marker of tubular damage and acute kidney injury. NGAL is 
covalently bound to neutrophil gelatinase in neutrophils and modulates matrix 
metalloproteinase-9 (MMP-9) activity by preventing degradation and thus preserving its 
enzymatic activity (42,43). MMP-9 destabilizes atherosclerotic plaques and is involved 
in tissue repair and vascular remodelling (44). As such serum NGAL is elevated in CAD 
and correlated with the disease severity (45). In a study of 673 STEMI by Helanova et 
al. BNP outperformed NGAL for the prediction of heart failure hospitalisation and 
inclusion of NGAL and BNP to a modified TIMI risk score even improved risk stratification 
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for mortality (46). In contrast our larger prospective study considering more variables 
and biomarkers currently used in daily practice and with considerably more statistical 
power could not confirm these findings. Thus, the prognostic value of NGAL in ACS 
patients is rather limited. 
The strengths of this study are its size providing proper statistical power, its 
prospective and multicenter design and the fact that an independent committee of 
experienced cardiologists adjudicated the events and that a certified core laboratory 
measured the evaluated markers.  
 
CONCLUSIONS 
In ACS patients, galectin-3 has moderate prognostic accuracy, provides statistically 
significant incremental value in some, but not all models, and that the magnitude of any 
improvement would seem of questionable clinical value. 
 
LIMITATIONS 
We did not evaluate the change in biomarker levels over time during the acute ACS 
event. Therefore, the optimal timing for measuring cystatin C, NGAL and galectin-3 
during hospitalization remains to be assessed. Rather we provide baseline values upon 
presentation immediately before revascularization mainly by primary PCI. It is possible, 
particularly in STEMI patients, that plasma or serum levels, respectively of these 
biomarkers change upon revascularization and this may affect their prognostic value. 
Also our data set for commonly used biomarkers as NT-proBNP and CRP was 
incomplete; we couldn't analyze the incremental value of galectin-3 when added to 
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FIGURE 1.  ROC CURVE FOR ALL-CAUSE MORTALITY AS WELL AS MACCE. AUCGAL-3 0.622 
VS. AUCCYSTATIN C 0.632 VS. AUCNGAL 0.592 FOR ALL-CAUSE MORTALITY. AUCGAL-3 0.751 VS. 
AUCCYSTATIN C 0.761 VS. AUCNGAL 0.721 FOR MACCE. THERE WAS NO SIGNIFICANT 
DIFFERENCE BETWEEN THESE VALUES. 
Figure 2. Smooth hr package Nonparametric estimates of the dependence of all-cause 
mortality  on different Galectin-3 levels among ACS patients (log hazard ratio, with 
95% confidence limits). The reference value of Galectin-3  with lowest hazard is  4.9, 
which corresponds  for a probability of zero. 
 
Figure 3. Cumulative survival in patients with different levels of serum Galectin-3 in 
Kaplan Meier Graph. Q (Quartile)1: <11.5 ng/ml, Q2: 11.5-14.3 ng/ml, Q3: 14.3-18.3 
ng/ml, Q4: >18.3 ng/ml. The survival rate in Q4 was significantly lower than in Q1, Q2 
and Q3 groups (p<0.001). 
 
Figure 4.a. The incremental predictive value of the addition of Galectin 3 to the GRACE 
score in predicting MACCE. Galectin 3 significantly improved the AUC from 0.6701 (95% 
asymptotic CI 0.614 – 0.726) to 0.6932 (0.636 – 0.750), p = 0.0474 Figure 4.b. The 
incremental predictive value of the addition of Galectin 3 to the GRACE score in 
predicting all-cause mortality. Galectin 3 significantly improved the AUC from 0.804 
(95% CI 0.749 – 0.858) to 0.820 (0.766 – 0.874), p = 0.0197 . 
 
Supplementary Figure 1. Study flow. The flow diagram shows patient enrollment and 
follow-up throughout the study. T1 signifies blood drawing performed at coronary 






















Table 1. Clinical and procedural characteristics in patients with and without MACCE. 
(Percentage within MACCE after one year) 
 
Table 2. Hazard ratios and confidence interval for predictors of major adverse cardiac 
and cerebrovascular Events (MACCE) as well as all-cause mortality 
 
Supplementary Table 1: Results of univariate logistic regression assessing the 
relationship between each biomarker and major adverse cardiac and cerebrovascular 
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Figure 2. Smooth HR package Nonparametric estimates of the dependence of all-
cause mortality on different Galectin-3 levels among ACS patients (log hazard ratio, 
with 95% confidence limits). The reference value of Galectin-3 with lowest hazard 
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incremental predictive value of the addition of Galectin 3 to the GRACE score in 
predicting all-cause mortality. Galectin 3 significantly improved the AUC from 0.804 
















Table 1. Clinical and procedural characteristics in patients with and without MACCE. 
(Percentage within MACCE after one year) 
 MACCE yes MACCE no p-value 
Sex female 41 (21.4%) 341 (20.8%) 0.851 
Coronary artery disease 41 (21.7%) 417 (25.8%) 0.251 
Peripheral vascular disease 16 (8.3%) 82 (5.0%) 0.061 
Diabetes 59 (30.7%) 278 (17.0%) <0.001 
Insulin dependent diabetes mellitus 26 (13.5%) 68 (4.2%) <0.001 
Hypertension 128 (66.7%) 932 (56.8%) 0.011 
Cholesterolemia 116 (60.4%) 1013 (61.8%) 0.754 
Myocardial infarction 46 (24.0%) 219 (13.4%) <0.001 
PCI history 54 (28.3%) 252 (15.4%) <0.001 
CABG history 24 (12.5%) 68 (4.1%) <0.001 
Congestive heart failure 8 (4.2%) 17 (1.0%) 0.003 
Dialysis 2 (1.0%) 6 (0.4%) 0.201 
Stroke 5 (2.6%) 33 (2.0%) 0.589 
Malignancy 30 (15.6%) 111 (6.8%) <0.001 
Lung disease 14 (7.3%) 67 (4.1%) 0.060 
Smoker 123 (65.8%) 1126 (69.5%) 0.316 
ACS   0.497 
Unstable angina pectoris 9 (4.7%) 62 (3.8%)  
Non STEMI 89 (46.4%) 710 (43.3%)  
STEMI 94 (49.0%) 868 (52.9%)  
Onset   0.747 
<24h 123 (64.7%) 1095 (67.2%)  
>24-48h 34 (17.9%) 258 (15.8%)  
>48-72h 20 (10.5%) 141 (8.7%)  
>72h-7d 11 (5.8%) 104 (6.4%)  
>7d 2 (1.1%) 32 (2.0%)  
Resuscitation 8 (4.2%) 49 (3.0%) 0.377 
KILLIP score 2 or higher 45 (23.8%) 194 (11.9%) <0.001 
Intraaortic balloon pump 12 (6.3%) 61 (3.7%) 0.115 
















Table 2. Hazard ratios and confidence interval for predictors of major adverse cardiac 
and cerebrovascular Events (MACCE) as well as all-cause mortality. 
MACCE all-cause Mortality 
 
Hazard 95% Confidence 
Interval 
p-value  Hazard 95% Confidence 
Interval 
p-value 
Lower Upper   Lower Upper  
Troponin 1.045 0.978 1.117 0.194  1.124 1.013 1.248 0.028 
Age 1.034 1.015 1.053 <0.001  1.083 1.048 1.120 <0.001 
MI history 1.419 0.957 2.105 0.082  1.417 0.779 2.577 0.254 
CABG 1.617 0.966 2.705 0.067  0.925 0.401 2.132 0.854 
Congestive 
heart failure 
1.820 0.866 3.823 0.114  1.784 0.624 5.099 0.280 
Malignancy 1.722 1.114 2.661 0.015  2.668 1.505 4.727 0.001 
Resuscitation 0.581 0.190 1.778 0.342  0.806 0.205 3.171 0.757 
IDDM 2.548 1.631 3.982 <0.001  2.374 1.233 4.568 0.010 
Galectin-3 1.025 1.012 1.037 <0.001  1.027 1.011 1.043 0.001 
Cystatin C 0.814 0.518 1.279 0.372  0.919 0.557 1.519 0.743 
Serum NGAL 1.001 0.998 1.005 0.478  1.003 0.999 1.008 0.156 





























































1. Study flow. The flow 
diagram shows patient 
enrollment and follow-up 
throughout the study. T1 
signifies blood drawing 
performed at coronary 
angiography.  
*Not analysed with biomarker 
kit or failed Measurement. 













Supplementary Table 1 
 
Results of univariate logistic regression assessing the relationship between each 
biomarker and major adverse cardiac and cerebrovascular events as well as mortality 
at one year 
 
Variable Odds Ratio (95% CI) P value 
MACCE 
Cystatin C (per mg/L increase) 2.01 (1.52-2.68) < 0.001 
NGAL (per ng/ml increase) 1.0056 (1.0033-1.0081) < 0.001 
Galectin-3 (per ng/ml increase) 1.039 (1.026-1.052) < 0.001 
MORTALITY   
Cystatin C (per mg/L increase) 2.99 (2.06 – 4.33) < 0.001 
NGAL (per ng/ml increase) 1.0103 (1.0072 – 1.0134) < 0.001 
Galectin-3 (per ng/ml increase) 1.057 (1.041 – 1.072) < 0.001 
 
 
